Cybin Inc (CYBN)

NYSE
Currency in USD
9.390
+0.020(+0.21%)
Closed
After Hours
9.250-0.140(-1.491%)
CYBN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
9.2209.450
52 wk Range
6.50019.851
Key Statistics
Edit
Prev. Close
9.37
Open
9.36
Day's Range
9.22-9.45
52 wk Range
6.5-19.851
Volume
162.36K
Average Volume (3m)
377.99K
1-Year Change
-30.8%
Book Value / Share
8.35
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CYBN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
102.801
Upside
+994.80%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Cybin Inc Company Profile

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. It also has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.

Compare CYBN to Peers and Sector

Metrics to compare
CYBN
Peers
Sector
Relationship
P/E Ratio
−2.6x−3.1x−0.6x
PEG Ratio
−0.15−0.040.00
Price/Book
1.1x0.3x2.6x
Price / LTM Sales
-2.0x3.1x
Upside (Analyst Target)
-126.4%52.8%
Fair Value Upside
Unlock26.3%8.4%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 102.801
(+994.80% Upside)

Earnings

Latest Release
Nov 13, 2024
EPS / Forecast
-- / -0.0248
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Cybin (CYBN) Stock Price Today?

The Cybin stock price today is 9.39

What Stock Exchange Does Cybin Trade On?

Cybin is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for Cybin?

The stock symbol for Cybin is "CYBN."

What Is the Cybin Market Cap?

As of today, Cybin market cap is 187.41M.

What is Cybin Earnings Per Share?

The Cybin EPS is -8.03.

From a Technical Analysis Perspective, Is CYBN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.